Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex
Tislelizumab plus chemotherapy as first-line treatment for recurrent or metastatic nasopharyngeal cancer: A multicenter phase 3 trial (RATIONALE-309)
PaperCitations, authors & open-access status
Tislelizumab plus chemotherapy as first-line treatment for recurrent or metastatic nasopharyngeal cancer: A multicenter phase 3 trial (RATIONALE-309) is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 223 citations, 2023 year and hybrid oa status.
223
Citations
2023
Year
hybrid
OA Status